Genomics and the family physician: Realizing the potential

American Family Physician

Volumn 70, Issue 9, 2004, Pages

  Collins, Francis ^a   Jenkins, Jean ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMATINIB; PROTEIN MLH1;

CANCER RISK; CHEMOTHERAPY; CLINICAL MEDICINE; COLON CANCER; COLONOSCOPY; COLORECTAL CANCER; DECISION MAKING; DIAGNOSTIC TEST; DNA DETERMINATION; DOCTOR PATIENT RELATION; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG MONITORING; EDITORIAL; EXCISION; FAMILY; FAMILY HISTORY; GENE MUTATION; GENE TECHNOLOGY; GENERAL PRACTICE; GENERAL PRACTITIONER; GENETIC COUNSELING; GENOMICS; HEALTH CARE; HEALTH CARE DELIVERY; HUMAN; HUMAN GENOME; LUNG CANCER; MEDICAL EDUCATION; MEDICAL GENETICS; MEDICAL SOCIETY; ONCOLOGY; PATIENT CARE; PHARMACOGENOMICS; POLYP; PRACTICE GUIDELINE; PREDICTION;

GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOMICS; HUMANS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHYSICIAN'S ROLE; PHYSICIANS, FAMILY; UNITED STATES;

EID: 7744235167     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (8)

1. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-32.
2. U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendations and rationale. Rockville, Md.: Agency for Healthcare Research and Quality, July 2002. Accessed online July 2004 at: http:// www.ahrq.gov/clinic/3rduspstf/colorectal/colorr.htm.
3. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
4. Green MR. Targeting targeted therapy. N Engl J Med 2004;350:2191-3.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
7. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004;22:247-306.
8. Collins FS. The case for a U.S. prospective cohort study of genes and environment. Nature 2004;429:475-7.